Inflammatory Bowel Disease Research Group Publications
Publications 2022
The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients
Scand J Gastroenterol, 1-7 (in press)
DOI 10.1080/00365521.2022.2029939, PubMed 35076321
Publications 2021
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study
Scand J Gastroenterol, 56 (10), 1163-1168
DOI 10.1080/00365521.2021.1955147, PubMed 34320885
Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
World J Gastroenterol, 27 (17), 2039-2053
DOI 10.3748/wjg.v27.i17.2039, PubMed 34007138
One year comprehensive prospective follow-up of achalasia patients after peroral endoscopic myotomy
Ann Med, 53 (1), 2225-2233
DOI 10.1080/07853890.2021.2005253, PubMed 34806501
Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Scand J Gastroenterol, 56 (8), 899-905
DOI 10.1080/00365521.2021.1922746, PubMed 34154494
Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study
Clin Epidemiol, 13, 287-294
DOI 10.2147/CLEP.S303797, PubMed 33935519
Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study
J Crohns Colitis, 15 (6), 969-979
DOI 10.1093/ecco-jcc/jjaa232, PubMed 33367569
Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic
Scand J Gastroenterol, 56 (5), 545-551
DOI 10.1080/00365521.2021.1901308, PubMed 33771086
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease
Dig Liver Dis, 53 (12), 1571-1579
DOI 10.1016/j.dld.2021.05.038, PubMed 34187768
Publications 2020
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 18 (10), 2295-2304.e2
DOI 10.1016/j.cgh.2020.02.014, PubMed 32068151
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BioDrugs, 34 (5), 681-694
DOI 10.1007/s40259-020-00438-7, PubMed 32965617
Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study
BMJ Open Gastroenterol, 7 (1), e000361
DOI 10.1136/bmjgast-2019-000361, PubMed 32337058
Association of Childbearing With a Short-Term Reduced Risk of Crohn Disease in Mothers
Am J Epidemiol, 189 (4), 294-304
DOI 10.1093/aje/kwz285, PubMed 31907543
Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
Scand J Gastroenterol, 55 (4), 436-441
DOI 10.1080/00365521.2020.1745879, PubMed 32252542
Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis
Gastroenterology, 160 (5), 1784-1798.e0
DOI 10.1053/j.gastro.2020.12.058, PubMed 33387530
Chronic inflammatory bowel disease and COVID-19
Tidsskr Nor Laegeforen, 140 (7)
DOI 10.4045/tidsskr.20.0230, PubMed 32378846
Health-related quality-of-life after radical cystectomy among Norwegian men and women compared to the general population
Scand J Urol, 54 (3), 181-187
DOI 10.1080/21681805.2020.1754906, PubMed 32343159
Self-esteem in patients with inflammatory bowel disease
Qual Life Res, 29 (7), 1839-1846
DOI 10.1007/s11136-020-02467-9, PubMed 32144613
The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study)
Inflamm Bowel Dis, 26 (1), 114-124
DOI 10.1093/ibd/izz105, PubMed 31127829
Health-related quality of life among 13-14 year old adolescents with overweight-a mixed methods approach
Health Qual Life Outcomes, 18 (1), 161
DOI 10.1186/s12955-020-01413-0, PubMed 32471437
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease
JHEP Rep, 3 (1), 100178
DOI 10.1016/j.jhepr.2020.100178, PubMed 33225252
Publications 2019
Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort
Scand J Gastroenterol, 54 (1), 41-48
DOI 10.1080/00365521.2018.1548646, PubMed 30650312
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside
Aliment Pharmacol Ther, 50 (4), 397-406
DOI 10.1111/apt.15386, PubMed 31264261
Outcome of peroral endoscopic myotomy (POEM) in treatment-naive patients. A systematic review
Scand J Gastroenterol, 54 (1), 1-7
DOI 10.1080/00365521.2018.1549271, PubMed 30650313
Pain Severity and Vitamin D Deficiency in IBD Patients
Nutrients, 12 (1)
DOI 10.3390/nu12010026, PubMed 31877637
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J Intern Med, 285 (6), 653-669
DOI 10.1111/joim.12880, PubMed 30762274
Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease
Scand J Gastroenterol, 54 (5), 571-576
DOI 10.1080/00365521.2019.1608467, PubMed 31050907
European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease
J Crohns Colitis, 13 (6), 673-685e
DOI 10.1093/ecco-jcc/jjz051, PubMed 30820529
Publications 2018
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
Inflamm Bowel Dis, 24 (5), 997-1004
DOI 10.1093/ibd/izx110, PubMed 29668901
Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis
Liver Int, 39 (2), 371-381
DOI 10.1111/liv.13979, PubMed 30269440
Anemia following Roux-en-Y gastric bypass for morbid obesity; a 5-year follow-up study
Scand J Gastroenterol, 53 (8), 917-922
DOI 10.1080/00365521.2018.1489892, PubMed 30231804
Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients
World J Gastroenterol, 24 (29), 3293-3301
DOI 10.3748/wjg.v24.i29.3293, PubMed 30090009
Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]
J Crohns Colitis, 12 (4), 389-393
DOI 10.1093/ecco-jcc/jjx152, PubMed 29186372
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Scand J Gastroenterol, 53 (6), 692-699
DOI 10.1080/00365521.2018.1463391, PubMed 29852793
Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease
Clin Gastroenterol Hepatol, 17 (5), 914-921.e5
DOI 10.1016/j.cgh.2018.05.004, PubMed 29775793
Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study
Scand J Gastroenterol, 53 (3), 273-278
DOI 10.1080/00365521.2018.1424935, PubMed 29313389
Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis
World J Gastroenterol, 24 (35), 4069-4076
DOI 10.3748/wjg.v24.i35.4069, PubMed 30254411
Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study
Scand J Gastroenterol, 53 (8), 952-957
DOI 10.1080/00365521.2018.1495258, PubMed 30205699
Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis
Aliment Pharmacol Ther, 48 (2), 179-189
DOI 10.1111/apt.14806, PubMed 29851098
Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study
Scand J Gastroenterol, 53 (10-11), 1250-1256
DOI 10.1080/00365521.2018.1518482, PubMed 30353756
Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study
J Crohns Colitis, 12 (1), 96-104
DOI 10.1093/ecco-jcc/jjx126, PubMed 28961700
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries
Gastroenterology, 155 (4), 1079-1089.e3
DOI 10.1053/j.gastro.2018.06.043, PubMed 29958857
Publications 2017
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Dig Dis, 35 (1-2), 74-82
DOI 10.1159/000449087, PubMed 28147370
Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study
J Crohns Colitis, 11 (3), 297-304
DOI 10.1093/ecco-jcc/jjw166, PubMed 27660339
Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study
J Crohns Colitis, 11 (10), 1213-1222
DOI 10.1093/ecco-jcc/jjx077, PubMed 28575481
Corrigendum: Malignancies in Patients with Inflammatory Bowel Disease (IBD): Results from 20 Years of Follow-up in the IBSEN (Inflammatory Bowel South-Eastern Norway) Study
J Crohns Colitis, 11 (12), 1511
DOI 10.1093/ecco-jcc/jjw218, PubMed 28039308
Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study
J Crohns Colitis, 11 (5), 571-577
DOI 10.1093/ecco-jcc/jjw193, PubMed 28453756
Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
Gastroenterol Res Pract, 2017, 2098293
DOI 10.1155/2017/2098293, PubMed 29225617
Psychometric limitations of the 13-item Sense of Coherence Scale assessed by Rasch analysis
BMC Psychol, 5 (1), 18
DOI 10.1186/s40359-017-0187-y, PubMed 28595651
Guanylate Cyclase C Activation Shapes the Intestinal Microbiota in Patients with Familial Diarrhea and Increased Susceptibility for Crohn's Disease
Inflamm Bowel Dis, 23 (10), 1752-1761
DOI 10.1097/MIB.0000000000001264, PubMed 28902124
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
J Hepatol, 66 (6), 1214-1222
DOI 10.1016/j.jhep.2017.01.019, PubMed 28161472
Publications 2016
Fluoride: a risk factor for inflammatory bowel disease?
Scand J Gastroenterol, 51 (9), 1019-24
DOI 10.1080/00365521.2016.1177855, PubMed 27199224
Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population
Scand J Gastroenterol, 52 (1), 100-106
DOI 10.1080/00365521.2016.1233577, PubMed 27603182
Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study
Inflamm Bowel Dis, 22 (1), 141-5
DOI 10.1097/MIB.0000000000000582, PubMed 26355464
Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study
Scand J Gastroenterol, 52 (3), 351-358
DOI 10.1080/00365521.2016.1256425, PubMed 27852169
Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study
Inflamm Bowel Dis, 22 (7), 1679-87
DOI 10.1097/MIB.0000000000000806, PubMed 27206016
Comparison of the Multiattribute Utility Instruments EQ-5D and SF-6D in a Europe-Wide Population-Based Cohort of Patients with Inflammatory Bowel Disease 10 Years after Diagnosis
Gastroenterol Res Pract, 2016, 5023973
DOI 10.1155/2016/5023973, PubMed 27630711
Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue
United European Gastroenterol J, 5 (5), 687-693
DOI 10.1177/2050640616674654, PubMed 28815032
Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease
Can J Gastroenterol Hepatol, 2016, 5624261
DOI 10.1155/2016/5624261, PubMed 27446848
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation
Mucosal Immunol, 9 (6), 1455-1465
DOI 10.1038/mi.2016.18, PubMed 26982597
Do no harm: no psychological harm from colorectal cancer screening
Br J Cancer, 114 (5), 497-504
DOI 10.1038/bjc.2016.14, PubMed 26867161
Patient-performed extraction of faecal calprotectin
Clin Chem Lab Med, 54 (8), 1357-63
DOI 10.1515/cclm-2015-1037, PubMed 26812797
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
Gut, 66 (4), 611-619
DOI 10.1136/gutjnl-2015-310500, PubMed 26887816
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function
United European Gastroenterol J, 5 (4), 532-541
DOI 10.1177/2050640616663453, PubMed 28588885
[Not Available]
Tidsskr Nor Laegeforen, 136 (14-15), 1266
DOI 10.4045/tidsskr.16.0477, PubMed 27554580
Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease
Gastroenterology, 151 (4), 660-669.e4
DOI 10.1053/j.gastro.2016.06.021, PubMed 27342213
The Use of Complementary and Alternative Medicine among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life
Gastroenterol Res Pract, 2016, 6453657
DOI 10.1155/2016/6453657, PubMed 28003821
Development of an index to define overall disease severity in IBD
Gut, 67 (2), 244-254
DOI 10.1136/gutjnl-2016-312648, PubMed 27780886
Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies
World J Gastrointest Pharmacol Ther, 7 (2), 235-41
DOI 10.4292/wjgpt.v7.i2.235, PubMed 27158539
Publications 2015
[Iron deficiency and iron deficiency anemia are global health problems]
Lakartidningen, 112
PubMed 25756711
Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis
Inflamm Bowel Dis, 21 (2), 337-44
DOI 10.1097/MIB.0000000000000272, PubMed 25569735
Patients' perceptions of quality of care and follow-up in inflammatory bowel disease
Scand J Gastroenterol, 51 (4), 434-41
DOI 10.3109/00365521.2015.1102319, PubMed 26635189
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin
J Crohns Colitis, 9 (2), 164-9
DOI 10.1093/ecco-jcc/jju015, PubMed 25518057
Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods
Scand J Clin Lab Invest, 75 (5), 355-61
DOI 10.3109/00365513.2015.1030765, PubMed 25856663
Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
Scand J Gastroenterol, 51 (5), 548-55
DOI 10.3109/00365521.2015.1117650, PubMed 26634305
Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease
Scand J Gastroenterol, 50 (9), 1183-4
DOI 10.3109/00365521.2015.1025830, PubMed 25772406
Challenges in the care of IBD in patients of all ages
Tidsskr. Nor. Laegeforen., 135 (2), 157
DOI 10.4045/tidsskr.14.1267
Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)
Scand J Gastroenterol, 50 (12), 1456-62
DOI 10.3109/00365521.2015.1064991, PubMed 26139389
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Hepatology, 62 (1), 188-97
DOI 10.1002/hep.27825, PubMed 25833813